Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Molecular Weight Dextran Sulfate in Islet Transplantation for Type 1 Diabetes
2008-001210-25Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ilb in diabetes mellitus type 1 (T1D) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Stimulated c-peptide level at 90 minutes during MMTT at 75±5 days after first islet infusion. Started Apr 2008; status: completed.
02
Drugs
ilb
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2008-001210-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001210-25.